FULGENT GENETICS, INC. Weighted Average Number of Shares Outstanding, Basic and Diluted
FULGENT GENETICS, INC. (FLGT) reported Weighted Average Number of Shares Outstanding, Basic and Diluted of 17.98 million shares for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-22.
Discontinued › Income Statement › Earnings Per Share
us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted · last filed 2019-03-22
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2016-12-31 was 17.48M shares, a 63.11% decline year-over-year.
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2016-09-30 was 12.85M shares.
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2015-12-31 was 47.37M shares.
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for the quarter ending 2015-09-30 was 0.00 shares.
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2018 was 17.98M shares, a 1.35% increase from fiscal 2017.
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2017 was 17.74M shares, a 29.39% increase from fiscal 2016.
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2016 was 13.71M shares, a 15.77% increase from fiscal 2015.
- FULGENT GENETICS, INC. weighted average number of shares outstanding, basic and diluted for fiscal 2015 was 11.84M shares.
| Period end | Weighted Average Number of Shares Outstanding, Basic and Diluted 3 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 6 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 9 month | Weighted Average Number of Shares Outstanding, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2018-12-31 | 17.98M shares 10-K · filed 2019-03-22 | |||
| 2017-12-31 | 17.74M shares 10-K · filed 2019-03-22 | |||
| 2016-12-31 | 17.48M shares derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-20 | 15.16M shares derived: average of 2 quarters · filed 2018-03-20 | 13.71M shares 10-K · filed 2018-03-20 | |
| 2016-09-30 | 12.85M shares 10-Q · filed 2016-11-14 | 12.46M shares 10-Q · filed 2016-11-14 | ||
| 2015-12-31 | 47.37M shares derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-17 | 23.68M shares derived: average of 2 quarters · filed 2017-03-17 | 11.84M shares 10-K · filed 2017-03-17 | |
| 2015-09-30 | 0.00 shares 10-Q · filed 2016-11-14 | 0.00 shares 10-Q · filed 2016-11-14 | ||
| 2014-12-31 | 0.00 shares 10-K · filed 2017-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |